|Bid||3.4000 x 1100|
|Ask||3.4200 x 1300|
|Day's Range||3.3550 - 3.4800|
|52 Week Range||1.2600 - 4.4400|
|Beta (5Y Monthly)||1.66|
|PE Ratio (TTM)||6.25|
|Earnings Date||Mar 07, 2023 - Mar 13, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.94|
Subscribe to Yahoo Finance Plus to view Fair Value for ASRT
LAKE FOREST, Ill., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced that it is raising its outlook for 2022 full-year net product sales to greater than $152 million, increased from its prior outlook calling for net product sales of greater than $141 million for the full year. The Company noted that net product sales to date in the fourth quarter
Here is how Kiniksa Pharmaceuticals, Ltd. (KNSA) and Assertio (ASRT) have performed compared to their sector so far this year.
Assertio (ASRT) delivered earnings and revenue surprises of 14.29% and 9.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?